Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Advanced Drainage Systems Inc (WMS) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Advanced Drainage Systems (WMS) trades at $125.19, down 0.59% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.49 beating estimates of $2.10. Revenue remains stable at $2.90B for 2025, while profitability metrics show robust ROE of 24.9% and net margin of 14%. Recent news highlights institutional buying activity and the release of Q1 2027 results showing 21% revenue growth.

WMS presents a compelling investment case with strong fundamentals and analyst consensus pointing to significant upside potential (target $188.20). However, near-term technical weakness and projected negative cash flow in 2026 warrant caution. The stock offers exposure to water infrastructure growth but faces execution risks from recent acquisitions and market volatility.